Vasodilatory and Metabolic Effects of Glucagon-like Peptide-1 in Periphery Circulation in Patients With and Without Type 2 Diabetes Mellitus
Information source: University Hospital, Gentofte, Copenhagen
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Type 2 Diabetes; Blod Pressure; Glucagon-like Peptide-1; Human Physiology; Blood Flow
Intervention: human glucagon-like peptide 1 (7-36)amide (Other); human glucagon-like peptide 1 (9-36)amide (Other)
Phase: N/A
Status: Completed
Sponsored by: University Hospital, Gentofte, Copenhagen Official(s) and/or principal investigator(s):
Jacob C Sivertsen, MD, Principal Investigator, Affiliation: University Hospital, Gentofte, Copenhagen
Summary
Diabetes and high blood pressure are risk factors for developing heart disease. An increase
in the number of diabetes patients is expected. This increases the number of patients with
heart disease, and since the vast majority with diabetes die from heart disease, it is
extremely important to investigate how these diseases can be prevented and treated.
Studies in animals have shown that intestinal hormone glucagon-like peptide-1 (GLP-1) can
expand blood vessels, thus lowering blood pressure, but it is not known whether the effects
is found in humans, which we will investigate.
Studies have also shown that GLP-1 lowers blood sugar, but it is unclear whether this is
solely due to increased insulin production, weight loss associated with GLP-1 intake or
GLP-1 has an effect on the muscles which increases the uptake of sugar. We investigate
whether GLP-1 enhances the absorption of sugar in the leg.
The investigators also examines whether these effects are greater in people with diabetes
then in healthy.
Clinical Details
Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science
Primary outcome: Femoral artery blood flow
Secondary outcome: Leg glucose uptake
Eligibility
Minimum age: 18 Years.
Maximum age: 75 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria:
- Written informed consent
- T2DM according to WHO's criteria (only T2DM subjects)
Exclusion Criteria:
- Anemia
- T1DM
- Severe liver or renal disease
- Severe heart disease
- Atrial fibrillation
Locations and Contacts
Gentofte Hospital, Department of Cardiology, Hellerup 2900, Denmark
Additional Information
Starting date: March 2012
Last updated: January 30, 2014
|
